SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is currently at the center of a heated debate as investors weigh concerns over the company's significant debt load and capital expenditure against its massive contracted cloud backlog. While some market participants are aggressively shorting the stock, citing risks related to AI infrastructure reliance and credit ratings, others are viewing the current price levels as a potential entry point based on the company's long-term enterprise growth strategy.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently a point of intense focus as investors weigh its potential as a key AI infrastructure power provider against a recent wave of short-seller reports questioning its supply chain integrity and growth projections. The community remains deeply divided, with many traders actively debating whether the recent price volatility represents a manipulation-driven shakeout of retail investors or a necessary correction based on valuation and project execution concerns.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is currently at the center of investor focus following the full commercialization of its Beacon Point data center campus, which was bolstered by a significant new long-term lease agreement. While the community is actively debating the company's valuation versus its peers and monitoring technical levels, the stock remains a key watch for those tracking the broader AI infrastructure buildout.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending due to active investor speculation regarding upcoming Phase 3 data for its COVID-Influenza Combination (CIC) vaccine and potential licensing partnerships that could monetize the company's Matrix-M technology. Community sentiment remains deeply divided, with some investors expressing frustration over management's communication silence, while others view recent patent filings as indicators of long-term strategic value and future revenue growth.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is facing intense volatility and downward pressure as investors grow frustrated with its significant underperformance compared to other fintech peers. The community is actively debating the company's long-term growth story versus its technical breakdown, with many traders using the stock as a frequent short-selling candidate while others advocate for patience ahead of upcoming earnings.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing intense volatility as investors weigh strong AI infrastructure demand and recent $2.8B in new contracts against concerns regarding equity dilution and management's capital allocation strategy. The stock remains a focal point for the community, with many debating if the current pullback serves as a strategic buying opportunity or an ongoing bear trap amid sector-wide rotation.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh strong delivery numbers and new government contracts against ongoing concerns over production execution and regulatory hurdles. The community remains polarized, with many highlighting the stock's significant backlog and undervaluation while others express deep frustration over price stagnation and the company's historical volatility.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis (PSNL) is currently at the center of market discussions following Tempus AIs strategic acquisition announcement at a set share price. The community is actively debating the terms of this deal, with significant concerns regarding the valuation, potential for competitive bidding wars, and the implications for major stakeholders like Merck.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is trending due to the unexpected departure of its CMO following a high-profile investigation, creating a volatile trading environment that the community is viewing as a potential buying opportunity. While investors express frustration with the recent news and volatility, the active discussion remains focused on the underlying clinical progress of NXC-201 and the belief that the stock's long-term value remains tied to its pipeline rather than temporary leadership turnover.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending as investors focus on its strong clinical pipeline, specifically positive results for safusidenib and the commercial potential of its approved lung cancer drug, Ibtrozi. The community is actively discussing its potential as a prime acquisition target following recent sector M&A activity, with long-term investors highlighting the CEO's track record and the company's solid balance sheet as key catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics Holdings Inc. (Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help...

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York: 2026 Jefferies...

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...

Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates

Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average   - Time to Sell?

Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below 200-Day Moving Average - What's Next...

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,00...

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

Equity

Neutral Sentiment

Long-term growth with defined downside

Reliable income

Digital asset exposure

Portfolio resilience

Which of the following best describes the primary outcome you are seeking from an ETF investment? 
 
*Sponsored by Calamos and S&amp;P Global

Stocktwits

Which of the following best describes the primary outcome you are seeking from an ETF investment? 
 
*Sponsored by Calamos and S&P Global

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARCTArcturus Therapeutics Holdings Inc

Fundamentals

Latest ARCT News